Investigating a new treatment for pulmonary fibrosis using a specific drug.
Use of the Src Family Kinase Inhibitor Saracatinib in the Treatment of Pulmonary Fibrosis
['FUNDING_OTHER'] · NATIONAL JEWISH HEALTH · NIH-10259731
This study is looking at whether a new medication called saracatinib can help people with idiopathic pulmonary fibrosis breathe better and feel healthier, since there aren't many good treatment options available right now.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | NATIONAL JEWISH HEALTH (nih funded) |
| Locations | 1 site (DENVER, UNITED STATES) |
| Trial ID | NIH-10259731 on ClinicalTrials.gov |
What this research studies
This research focuses on idiopathic pulmonary fibrosis (IPF), a serious lung disease that currently has limited treatment options. The team is exploring the use of saracatinib, a Src kinase inhibitor, to see if it can provide a more effective and safer therapy for patients with IPF. By analyzing data from previous studies and conducting clinical trials, the researchers aim to determine how well this drug can improve lung function and quality of life for patients suffering from this condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with idiopathic pulmonary fibrosis who are seeking new treatment options.
Not a fit: Patients with other forms of lung disease or those who do not have idiopathic pulmonary fibrosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment option that significantly improves lung function and quality of life for patients with pulmonary fibrosis.
How similar studies have performed: Previous research has shown promise in using targeted therapies for pulmonary fibrosis, but the specific approach with saracatinib is novel.
Where this research is happening
DENVER, UNITED STATES
- NATIONAL JEWISH HEALTH — DENVER, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: DOWNEY, GREGORY PAUL — NATIONAL JEWISH HEALTH
- Study coordinator: DOWNEY, GREGORY PAUL
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.